We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+2.69%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$8.16B
AUM Growth
+$296M
Cap. Flow
-$1.61B
Cap. Flow %
-19.71%
Top 10 Hldgs %
74.41%
Holding
114
New
7
Increased
22
Reduced
9
Closed
9

Top Buys

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$80.1M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$65.5M
3
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$58.8M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$48.9M
5
ARAV
Aravive, Inc. Common Stock
ARAV
+$35.8M

Top Sells

Rank Stock Value
1
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$84.5M
2
CHTP
CHELSEA THERAPEUTICS INT'L LTD
CHTP
+$37.3M
3
HALO icon
Halozyme
HALO
+$24.8M
4
GILD icon
Gilead Sciences
GILD
+$23.4M
5
QCOR
QUESTCOR PHARMA INC
QCOR
+$18.6M

Sector Composition

Rank Sector Weight
1 Healthcare 39.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARWR icon
26
Arrowhead Research
ARWR
$12.1B
$20.5M 0.25%
1,430,802
+698,740
+95% +$9.16M
TGTX icon
27
TG Therapeutics
TGTX
$8.16B
$20.3M 0.25%
2,160,965
– –
XNPT
28
DELISTED
XENOPORT, INC.
XNPT
$19.5M 0.24%
4,034,112
– –
PGNX
29
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$19.2M 0.23%
4,449,797
– –
SLXP
30
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$16.5M 0.2%
133,721
+130,100
+3,593% +$14.4M
AEGR
31
DELISTED
Aegerion Pharmaceuticals
AEGR
$13.3M 0.16%
413,922
-100,000
-19% -$3.72M
OMER icon
32
Omeros
OMER
$834M
$13.1M 0.16%
753,804
– –
KYTH
33
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$11.9M 0.15%
311,255
– –
NGNE icon
34
Neurogene
NGNE
$645M
$11.4M 0.14%
60,593
– –
QLTI
35
DELISTED
QLT Inc
QLTI
$9.49M 0.12%
1,535,863
– –
AGIO icon
36
Agios Pharmaceuticals
AGIO
$2.09B
$9.16M 0.11%
199,893
– –
NBIX icon
37
Neurocrine Biosciences
NBIX
$18.3B
$8.23M 0.1%
554,590
+106,716
+24% +$1.51M
SGMO
38
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$7.98M 0.1%
522,764
– –
OSIR
39
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
$7.98M 0.1%
510,606
+149,076
+41% +$2.19M
INFI
40
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$7.95M 0.1%
624,050
– –
BLUE
41
DELISTED
bluebird bio
BLUE
$7.65M 0.09%
15,306
– –
AERI
42
DELISTED
Aerie Pharmaceuticals
AERI
$7.42M 0.09%
299,356
– –
MTEM
43
DELISTED
Molecular Templates, Inc.
MTEM
$7.23M 0.09%
11,069
– –
SGYP
44
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$7.16M 0.09%
1,758,271
– –
IRWD icon
45
Ironwood Pharmaceuticals
IRWD
$598M
$6.84M 0.08%
532,715
– –
MGNX icon
46
MacroGenics
MGNX
$234M
$6.78M 0.08%
311,891
+215,726
+224% +$4.54M
EPZM
47
DELISTED
Epizyme, Inc
EPZM
$6.66M 0.08%
214,012
– –
ARRY
48
DELISTED
Array Biopharma Inc
ARRY
$6.54M 0.08%
1,433,797
– –
WINT
49
DELISTED
Windtree Therapeutics Inc
WINT
$6.5M 0.08%
260,866
– –
ABUS icon
50
Arbutus Biopharma
ABUS
$853M
$6.32M 0.08%
484,156
– –
1
2
3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2014 Portfolio in Review

As of Q2 2014, Baker Bros. Advisors held 114 positions worth $8.16B, up 3.8% from $7.87B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Baker Bros. Advisors withdrew a net $1.61B in Q2 2014, closing 9 positions and reducing 9 holdings. Its most notable exit was Intercept Pharmaceuticals, Inc., an estimated $84.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 40% of assets, down from 43% a quarter earlier.

Against the trend, Baker Bros. Advisors opened a new position in Aravive, Inc. Common Stock worth $34.9M.

  • Baker Bros. Advisors's largest Q2 2014 buy was Aravive, Inc. Common Stock: 207,648 shares worth $34.9M.
  • Baker Bros. Advisors added most to PHARMACYCLICS INC in Q2 2014, an estimated $80.1M increase.
  • Baker Bros. Advisors's biggest Q2 2014 reduction was Halozyme, cutting an estimated $24.8M.
  • Baker Bros. Advisors fully exited Intercept Pharmaceuticals, Inc. in Q2 2014, selling an estimated $84.5M.
  • Baker Bros. Advisors's ten largest holdings make up 74% of its $8.16B portfolio in Q2 2014.
  • Baker Bros. Advisors opened 7 new positions and closed 9 in Q2 2014.
  • Baker Bros. Advisors's portfolio value rose 3.8% quarter-over-quarter to $8.16B.

Based on Baker Bros. Advisors's 13F filing for Q2 2014, filed 14 Aug 2014.